Chronic lymphocytic leukaemia trials in Hungary
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Budapest IX, Budapest VIII, Pécs, Szeged
- Age
- 18 years and over
- People
- 249 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01 - Phase 4Taking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Budapest, Debrecen
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Budapest, Debrecen, Nyíregyháza, Pécs
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 3Taking peopleA Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- Where
- Budapest IX, Budapest XII, Debrecen, Eger, Győr, Szeged, Székesfehérvár, Szekszárd
- Age
- 18 years and over
- People
- 386 worldwide
- Run by
- Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00 - Phase 2Taking peopleA Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) and a Bcell Lymphoma-2 Inhibitor (BCL-2i) (DAYBreak CLL-201)
- Where
- Debrecen
- Age
- 18 years and over
- People
- 45 worldwide
- Run by
- Nurix Therapeutics Inc.
See details and how to join2025-521088-10-00 · EU 2025-521088-10-00 - Phase 1/2Taking peopleA Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Debrecen, Kaposvár, Nyíregyháza
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to join2024-515654-25-00 · EU 2024-515654-25-00 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Debrecen, Szombathely
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - Phase 3Taking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Budapest VIII, Debrecen, Nyíregyháza
- Age
- 18 years to 99 years
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00